ArticleCureus2025
Incidence of PEG-Asparaginase-Induced Pancreatitis in Children During Acute Lymphoblastic Leukemia Treatment: A Multicenter Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nomogram-based prediction of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a retrospective study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute lymphoblastic leukemia (ALL) is the most common pediatric cancer globally. PEG-asparaginase (PEG-ASPA), a cornerstone of ALL treatment, significantly improves outcomes but is associated with serious toxicities, including acute pancreatitis (AP). This study evaluates the incidence and associated risk factors of PEG-ASPA-induced AP among pediatric ALL patients in Saudi Arabia.
methodsThis multicenter retrospective cohort study included pediatric ALL patients treated with PEG-ASPA between January 2019 and October 2023 at three tertiary Saudi centers. Data included demographics, risk stratification, PEG-ASPA doses, and toxicity. AP was defined per CTCAE v5.0 criteria. A multivariate logistic regression model was used to evaluate risk factors.
resultsOf 322 pediatric patients, 5% (n=16) developed AP. Events were more frequent in children >10 years old (44%) and during consolidation (38%) and interim maintenance 2 (38%) phases. Multivariate analysis showed that age >10 years (OR=3.65), high-risk protocols (OR=2.07), and >5 PEG-ASPA doses (OR=1.58) were associated with increased AP risk. Most cases were grade 2 or 3 and resolved with supportive care.
conclusionThe incidence of PEG-ASPA-induced AP among pediatric ALL patients in Saudi Arabia is consistent with international data. Higher age, intensive protocols, and cumulative dosing may increase risk. Routine monitoring of pancreatic enzymes and triglycerides prior to PEG-ASPA administration is recommended to enhance early detection and reduce the risk of severe toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.